Dopaminergic Mechanisms in Parkinson's Disease Management

Parkinson’s disease is characterised by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to striatal dopamine depletion and the emergence of motor symptoms such as bradykinesia, rigidity and tremor. Current management strategies centre on restoration of dopaminergic signalling, primarily through the administration of levodopa, dopamine receptor agonists and inhibitors of dopamine metabolism. Mechanistic research has elucidated cellular and molecular pathways by which dopamine synthesis, release and receptor stimulation can be optimised, while ameliorating complications such as motor fluctuations and dyskinesia. Recent advances have focused on computational modelling of striatal dopamine dynamics, the role of energy metabolism and oxidative stress in dopaminergic neuron vulnerability, and novel drug delivery and sensing technologies to refine dosage and timing. Together, these efforts aim to extend the therapeutic window, reduce adverse effects and lay the groundwork for neuroprotective and disease-modifying interventions.

Research from Nature Portfolio

A comprehensive subcellular computational model of the substantia nigra pars compacta cell has demonstrated that deficits in energy substrates, notably glucose, precipitate adenosine triphosphate depletion that in turn drives pathological cascades including alpha-synuclein aggregation, reactive oxygen species accumulation, calcium dysregulation and impaired dopamine handling. This model suggests that hypoglycaemia has a more pronounced effect than hypoxia on ATP reserves and highlights energy deficiency as a unifying factor in dopaminergic cell loss. By integrating molecular-level processes, the framework offers insights into how metabolic interventions might bolster neuronal resilience and modulate dopaminergic mechanisms in Parkinson’s disease management.

Dopaminergic Mechanisms in Parkinson's Disease Management publication trend

The graph below shows the total number of articles in dopaminergic mechanisms in parkinson's disease management across all publications each year (not limited to Nature Index journals).

Technical terms

Levodopa (L-DOPA): The immediate metabolic precursor of dopamine, used to replenish depleted dopamine levels in the brain.

Substantia nigra pars compacta (SNc): A midbrain region containing dopaminergic neurons whose degeneration is central to Parkinson’s disease.

Adenosine triphosphate (ATP): The primary intracellular energy currency, whose depletion in dopaminergic neurons contributes to neurodegenerative cascades.

Reactive oxygen species (ROS): Highly reactive molecules derived from oxygen that can induce oxidative damage to cellular components.

Physisorption: A form of adsorption characterised by weak van der Waals forces, relevant in sensor design for drug detection.

Oxidative phosphorylation: Mitochondrial process generating ATP via electron transport and chemiosmotic coupling.

References

1. Tailoring adsorbents for levodopa detection: a DFT study on Pt-encapsulated fullerene systems. RSC Advances (2024).
2. Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration. Scientific Reports (2021).
3. Impairment of neuronal mitochondrial function by l-DOPA in the absence of oxygen-dependent auto-oxidation and oxidative cell damage. Cell Death Discovery (2021).
4. A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease. Frontiers in Neuroscience (2022).